Apogee Therapeutics (APGE) Competitors

$81.39 +3.12 (+3.99%)

Closing price 04:00 PM Eastern

Extended Trading

$81.48 +0.09 (+0.12%)

As of 06:53 PM Eastern

APGE vs. VTRS, MRNA, GMAB, ASND, and RGC

Should you buy Apogee Therapeutics stock or one of its competitors? MarketBeat compares Apogee Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Apogee Therapeutics include Viatris (VTRS), Moderna (MRNA), Genmab A/S (GMAB), Ascendis Pharma A/S (ASND), and Regencell Bioscience (RGC). These companies are all part of the "pharmaceutical products" industry.

How does Apogee Therapeutics compare to Viatris?

Apogee Therapeutics (NASDAQ:APGE) and Viatris (NASDAQ:VTRS) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings.

Apogee Therapeutics has higher earnings, but lower revenue than Viatris. Viatris is trading at a lower price-to-earnings ratio than Apogee Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.33	N/A
Viatris	$14.30B	1.35	-$3.51B	-$0.26	N/A

79.0% of Apogee Therapeutics shares are owned by institutional investors. Comparatively, 79.9% of Viatris shares are owned by institutional investors. 24.3% of Apogee Therapeutics shares are owned by insiders. Comparatively, 0.3% of Viatris shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Apogee Therapeutics has a net margin of 0.00% compared to Viatris' net margin of -2.04%. Viatris' return on equity of 19.04% beat Apogee Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apogee Therapeutics	N/A	-32.64%	-31.25%
Viatris	-2.04%	19.04%	7.62%

Apogee Therapeutics presently has a consensus price target of $112.73, indicating a potential upside of 38.51%. Viatris has a consensus price target of $16.43, indicating a potential downside of 0.97%. Given Apogee Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Apogee Therapeutics is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apogee Therapeutics	1 Sell rating(s)	4 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.78
Viatris	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38

Apogee Therapeutics has a beta of 0.69, meaning that its stock price is 31% less volatile than the broader market. Comparatively, Viatris has a beta of 0.88, meaning that its stock price is 12% less volatile than the broader market.

In the previous week, Viatris had 3 more articles in the media than Apogee Therapeutics. MarketBeat recorded 6 mentions for Viatris and 3 mentions for Apogee Therapeutics. Viatris' average media sentiment score of 0.28 beat Apogee Therapeutics' score of 0.18 indicating that Viatris is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Apogee Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Viatris	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Viatris beats Apogee Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Apogee Therapeutics compare to Moderna?

Moderna (NASDAQ:MRNA) and Apogee Therapeutics (NASDAQ:APGE) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation, dividends and media sentiment.

Apogee Therapeutics has lower revenue, but higher earnings than Moderna. Apogee Therapeutics is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$1.94B	9.82	-$2.82B	-$8.15	N/A
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.33	N/A

In the previous week, Moderna had 4 more articles in the media than Apogee Therapeutics. MarketBeat recorded 7 mentions for Moderna and 3 mentions for Apogee Therapeutics. Moderna's average media sentiment score of 0.20 beat Apogee Therapeutics' score of 0.18 indicating that Moderna is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moderna	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Apogee Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

75.3% of Moderna shares are held by institutional investors. Comparatively, 79.0% of Apogee Therapeutics shares are held by institutional investors. 10.8% of Moderna shares are held by insiders. Comparatively, 24.3% of Apogee Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Moderna has a beta of 1.05, suggesting that its stock price is 5% more volatile than the broader market. Comparatively, Apogee Therapeutics has a beta of 0.69, suggesting that its stock price is 31% less volatile than the broader market.

Moderna presently has a consensus target price of $35.73, suggesting a potential downside of 25.74%. Apogee Therapeutics has a consensus target price of $112.73, suggesting a potential upside of 38.51%. Given Apogee Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Apogee Therapeutics is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	5 Sell rating(s)	12 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.84
Apogee Therapeutics	1 Sell rating(s)	4 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.78

Apogee Therapeutics has a net margin of 0.00% compared to Moderna's net margin of -143.55%. Moderna's return on equity of -26.64% beat Apogee Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-143.55%	-26.64%	-19.32%
Apogee Therapeutics	N/A	-32.64%	-31.25%

Summary

Apogee Therapeutics beats Moderna on 9 of the 15 factors compared between the two stocks.

How does Apogee Therapeutics compare to Genmab A/S?

Genmab A/S (NASDAQ:GMAB) and Apogee Therapeutics (NASDAQ:APGE) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, media sentiment, valuation and risk.

Genmab A/S has higher revenue and earnings than Apogee Therapeutics. Apogee Therapeutics is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$3.72B	4.56	$963M	$1.32	20.61
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.33	N/A

Genmab A/S has a net margin of 21.05% compared to Apogee Therapeutics' net margin of 0.00%. Genmab A/S's return on equity of 15.34% beat Apogee Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	21.05%	15.34%	8.94%
Apogee Therapeutics	N/A	-32.64%	-31.25%

7.1% of Genmab A/S shares are owned by institutional investors. Comparatively, 79.0% of Apogee Therapeutics shares are owned by institutional investors. 1.5% of Genmab A/S shares are owned by insiders. Comparatively, 24.3% of Apogee Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Apogee Therapeutics had 1 more articles in the media than Genmab A/S. MarketBeat recorded 3 mentions for Apogee Therapeutics and 2 mentions for Genmab A/S. Genmab A/S's average media sentiment score of 0.41 beat Apogee Therapeutics' score of 0.18 indicating that Genmab A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Apogee Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Genmab A/S has a beta of 0.86, meaning that its share price is 14% less volatile than the broader market. Comparatively, Apogee Therapeutics has a beta of 0.69, meaning that its share price is 31% less volatile than the broader market.

Genmab A/S currently has a consensus target price of $39.07, suggesting a potential upside of 43.59%. Apogee Therapeutics has a consensus target price of $112.73, suggesting a potential upside of 38.51%. Given Genmab A/S's stronger consensus rating and higher possible upside, research analysts plainly believe Genmab A/S is more favorable than Apogee Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.83
Apogee Therapeutics	1 Sell rating(s)	4 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.78

Summary

Genmab A/S beats Apogee Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Apogee Therapeutics compare to Ascendis Pharma A/S?

Ascendis Pharma A/S (NASDAQ:ASND) and Apogee Therapeutics (NASDAQ:APGE) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations, profitability and earnings.

Ascendis Pharma A/S has a beta of 0.41, meaning that its stock price is 59% less volatile than the broader market. Comparatively, Apogee Therapeutics has a beta of 0.69, meaning that its stock price is 31% less volatile than the broader market.

Apogee Therapeutics has lower revenue, but higher earnings than Ascendis Pharma A/S. Apogee Therapeutics is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$814.57M	18.48	-$258M	$8.67	27.84
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.33	N/A

Ascendis Pharma A/S currently has a consensus target price of $295.39, suggesting a potential upside of 22.40%. Apogee Therapeutics has a consensus target price of $112.73, suggesting a potential upside of 38.51%. Given Apogee Therapeutics' higher possible upside, analysts plainly believe Apogee Therapeutics is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	3.00
Apogee Therapeutics	1 Sell rating(s)	4 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.78

In the previous week, Ascendis Pharma A/S had 3 more articles in the media than Apogee Therapeutics. MarketBeat recorded 6 mentions for Ascendis Pharma A/S and 3 mentions for Apogee Therapeutics. Ascendis Pharma A/S's average media sentiment score of 1.14 beat Apogee Therapeutics' score of 0.18 indicating that Ascendis Pharma A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Apogee Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

79.0% of Apogee Therapeutics shares are held by institutional investors. 40.0% of Ascendis Pharma A/S shares are held by company insiders. Comparatively, 24.3% of Apogee Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Ascendis Pharma A/S has a net margin of 57.87% compared to Apogee Therapeutics' net margin of 0.00%. Ascendis Pharma A/S's return on equity of 0.00% beat Apogee Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	57.87%	N/A	-8.37%
Apogee Therapeutics	N/A	-32.64%	-31.25%

Summary

Ascendis Pharma A/S beats Apogee Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Apogee Therapeutics compare to Regencell Bioscience?

Apogee Therapeutics (NASDAQ:APGE) and Regencell Bioscience (NASDAQ:RGC) are both pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, profitability, analyst recommendations, risk, valuation and dividends.

Regencell Bioscience's return on equity of 0.00% beat Apogee Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apogee Therapeutics	N/A	-32.64%	-31.25%
Regencell Bioscience	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.33	N/A
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A

79.0% of Apogee Therapeutics shares are owned by institutional investors. Comparatively, 0.1% of Regencell Bioscience shares are owned by institutional investors. 24.3% of Apogee Therapeutics shares are owned by insiders. Comparatively, 2.0% of Regencell Bioscience shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Apogee Therapeutics presently has a consensus price target of $112.73, indicating a potential upside of 38.51%. Given Apogee Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Apogee Therapeutics is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apogee Therapeutics	1 Sell rating(s)	4 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.78
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Regencell Bioscience had 15 more articles in the media than Apogee Therapeutics. MarketBeat recorded 18 mentions for Regencell Bioscience and 3 mentions for Apogee Therapeutics. Apogee Therapeutics' average media sentiment score of 0.18 beat Regencell Bioscience's score of 0.00 indicating that Apogee Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Apogee Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Regencell Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	17 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Apogee Therapeutics has a beta of 0.69, indicating that its share price is 31% less volatile than the broader market. Comparatively, Regencell Bioscience has a beta of 1.88, indicating that its share price is 88% more volatile than the broader market.

Summary

Apogee Therapeutics beats Regencell Bioscience on 7 of the 12 factors compared between the two stocks.

Get Apogee Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding APGE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

APGE vs. The Competition

Export

Metric	Apogee Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.85B	$3.30B	$6.27B	$12.27B
Dividend Yield	N/A	2.34%	2.80%	5.32%
P/E Ratio	-18.80	18.73	20.85	25.19
Price / Sales	N/A	182.81	511.68	61.11
Price / Cash	N/A	124.58	43.09	54.25
Price / Book	4.01	6.81	9.90	6.95
Net Income	-$255.84M	$24.18M	$3.55B	$335.25M
7 Day Performance	-3.04%	-0.25%	-0.30%	-0.70%
1 Month Performance	-10.48%	-4.58%	-2.34%	-0.90%
1 Year Performance	101.76%	55.65%	30.89%	29.67%

Apogee Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
APGE Apogee Therapeutics	2.4715 of 5 stars	$81.39 +4.0%	$112.73 +38.5%	+96.5%	$4.85B	N/A	N/A	91
VTRS Viatris	2.5373 of 5 stars	$16.18 -2.0%	$16.43 +1.6%	+84.6%	$18.82B	$14.30B	N/A	30,000	Analyst Forecast
MRNA Moderna	1.3256 of 5 stars	$46.14 -4.1%	$35.73 -22.6%	+73.2%	$18.29B	$1.94B	N/A	4,700	Insider Trade
GMAB Genmab A/S	4.1507 of 5 stars	$25.61 -2.9%	$39.07 +52.6%	+27.3%	$15.99B	$3.72B	19.42	3,029	Gap Down
ASND Ascendis Pharma A/S	4.0773 of 5 stars	$239.74 -0.3%	$295.39 +23.2%	+48.4%	$14.84B	$814.57M	27.44	1,189	Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:APGE) was last updated on 5/20/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Apogee Therapeutics (APGE) Competitors

APGE vs. VTRS, MRNA, GMAB, ASND, and RGC

How does Apogee Therapeutics compare to Viatris?

Summary

How does Apogee Therapeutics compare to Moderna?

Summary

How does Apogee Therapeutics compare to Genmab A/S?

Summary

How does Apogee Therapeutics compare to Ascendis Pharma A/S?

Summary

How does Apogee Therapeutics compare to Regencell Bioscience?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APGE vs. The Competition

Apogee Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Apogee Therapeutics (APGE) Competitors

APGE vs. VTRS, MRNA, GMAB, ASND, and RGC

How does Apogee Therapeutics compare to Viatris?

Which has preferable earnings & valuation, APGE or VTRS?

Do insiders and institutionals believe in APGE or VTRS?

Is APGE or VTRS more profitable?

Do analysts recommend APGE or VTRS?

Which has more volatility and risk, APGE or VTRS?

Does the media favor APGE or VTRS?

Summary

How does Apogee Therapeutics compare to Moderna?

Which has higher earnings & valuation, MRNA or APGE?

Does the media prefer MRNA or APGE?

Do insiders & institutionals hold more shares of MRNA or APGE?

Which has more volatility & risk, MRNA or APGE?

Do analysts recommend MRNA or APGE?

Is MRNA or APGE more profitable?

Summary

How does Apogee Therapeutics compare to Genmab A/S?

Which has preferable earnings & valuation, GMAB or APGE?

Is GMAB or APGE more profitable?

Do insiders & institutionals hold more shares of GMAB or APGE?

Does the media refer more to GMAB or APGE?

Which has more risk and volatility, GMAB or APGE?

Do analysts rate GMAB or APGE?

Summary

How does Apogee Therapeutics compare to Ascendis Pharma A/S?

Which has more risk & volatility, ASND or APGE?

Which has better earnings and valuation, ASND or APGE?

Do analysts recommend ASND or APGE?

Does the media favor ASND or APGE?

Do insiders & institutionals believe in ASND or APGE?

Is ASND or APGE more profitable?

Summary

How does Apogee Therapeutics compare to Regencell Bioscience?

Is APGE or RGC more profitable?

Which has preferable valuation & earnings, APGE or RGC?

Do institutionals and insiders believe in APGE or RGC?

Do analysts prefer APGE or RGC?

Does the media prefer APGE or RGC?

Which has more risk & volatility, APGE or RGC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APGE vs. The Competition

Apogee Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools